Literature DB >> 31625721

Co-delivery of Bee Venom Melittin and a Photosensitizer with an Organic-Inorganic Hybrid Nanocarrier for Photodynamic Therapy and Immunotherapy.

Haojie Liu1, Yan Hu2, Yajie Sun2, Chao Wan2, Zhanjie Zhang2, Xiaomeng Dai2, Zihan Lin1, Qianyuan He1, Zhe Yang1, Piao Huang1, Yuxuan Xiong1, Jinguo Cao1, Xu Chen1, Qi Chen1, Jonathan F Lovell3, Zushun Xu1, Honglin Jin2, Kunyu Yang2.   

Abstract

Photodynamic therapy (PDT) is a clinical cancer treatment modality based on the induction of therapeutic reactive oxygen species (ROS), which can trigger immunogenic cell death (ICD). With the aim of simultaneously improving both PDT-mediated intracellular ROS production and ICD levels, we designed a serum albumin (SA)-coated boehmite ("B"; aluminum hydroxide oxide) organic-inorganic scaffold that could be loaded with chlorin e6 (Ce6), a photosensitizer, and a honey bee venom melittin (MLT) peptide, denoted Ce6/MLT@SAB. Ce6/MLT@SAB was anchored by a boehmite nanorod structure and exhibited particle size of approximately 180 nm. Ce6/MLT@SAB could significantly reduce hemolysis relative to that of free MLT, while providing MLT-enhanced PDT antitumor effects in vitro. Compared with Ce6@SAB, Ce6/MLT@SAB improved Ce6 penetration of cancer cells both in vitro and in vivo, thereby providing enhanced intracellular ROS generation with 660 nm light treatment. Following phototreatment, Ce6/MLT@SAB-treated cells displayed significantly improved levels of ICD and abilities to activate dendritic cells. In the absence of laser irradiation, multidose injection of Ce6/MLT@SAB could delay the growth of subcutaneous murine tumors by more than 60%, compared to controls. When combined with laser irradiation, a single injection and phototreatment with Ce6/MLT@SAB eradicated one-third of subcutaneous tumors in treated mice. The addition of an immune checkpoint blockade to Ce6/MLT@SAB phototreatment further augmented antitumor effects, generating increased numbers of CD4+ and CD8+ T cells in tumors with concomitant reduction of myeloid-derived suppressor cells.

Entities:  

Keywords:  anti-PD-1; cancer immunotherapy; immune checkpoints; immunogenic cell death; melittin; photodynamic therapy

Year:  2019        PMID: 31625721     DOI: 10.1021/acsnano.9b04181

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  27 in total

1.  Development of D-melittin polymeric nanoparticles for anti-cancer treatment.

Authors:  Shixian Lv; Meilyn Sylvestre; Kefan Song; Suzie H Pun
Journal:  Biomaterials       Date:  2021-08-23       Impact factor: 15.304

2.  Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.

Authors:  Chengqiong Mao; Stacy Yeh; Juan Fu; Mercedes Porosnicu; Alexandra Thomas; Gregory L Kucera; Konstantinos I Votanopoulos; Shaomin Tian; Xin Ming
Journal:  Sci Transl Med       Date:  2022-06-08       Impact factor: 19.319

Review 3.  Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy.

Authors:  Su-Ran Li; Fang-Yi Huo; Han-Qi Wang; Jing Wang; Chun Xu; Bing Liu; Lin-Lin Bu
Journal:  J Nanobiotechnology       Date:  2022-06-14       Impact factor: 9.429

4.  Dimensional Reduction Enhances Photodynamic Therapy of Metal-Organic Nanophotosensitizers.

Authors:  Taokun Luo; Yingjie Fan; Jianming Mao; Eric Yuan; Eric You; Ziwan Xu; Wenbin Lin
Journal:  J Am Chem Soc       Date:  2022-03-17       Impact factor: 16.383

5.  Multi-antitumor therapy and synchronous imaging monitoring based on exosome.

Authors:  Ruijie Qian; Boping Jing; Dawei Jiang; Yongkang Gai; Ziyang Zhu; Xiaojuan Huang; Yu Gao; Xiaoli Lan; Rui An
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-29       Impact factor: 10.057

6.  Multifunctional Nanodrug Mediates Synergistic Photodynamic Therapy and MDSCs-Targeting Immunotherapy of Colon Cancer.

Authors:  Dongbing Ding; Huihai Zhong; Rongpu Liang; Tianyun Lan; Xudong Zhu; Shengxin Huang; Yong Wang; Jun Shao; Xintao Shuai; Bo Wei
Journal:  Adv Sci (Weinh)       Date:  2021-05-21       Impact factor: 16.806

Review 7.  Emerging nanomedicines for effective breast cancer immunotherapy.

Authors:  Amirhossein Bahreyni; Yasir Mohamud; Honglin Luo
Journal:  J Nanobiotechnology       Date:  2020-12-09       Impact factor: 10.435

Review 8.  Immunogenic Cell Death-Based Cancer Vaccines.

Authors:  Ming-Zhu Jin; Xi-Peng Wang
Journal:  Front Immunol       Date:  2021-05-31       Impact factor: 7.561

9.  Half-life determination of inorganic-organic hybrid nanomaterials in mice using laser-induced breakdown spectroscopy.

Authors:  Yanwu Chu; Zhanjie Zhang; Qianyuan He; Feng Chen; Ziqian Sheng; Deng Zhang; Honglin Jin; Fagang Jiang; Lianbo Guo
Journal:  J Adv Res       Date:  2020-05-16       Impact factor: 10.479

Review 10.  The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

Authors:  Jinmei Jin; Ye Wu; Jinjiao Chen; Yiwen Shen; Lijun Zhang; Hong Zhang; Lili Chen; Hebao Yuan; Hongzhuan Chen; Weidong Zhang; Xin Luan
Journal:  Theranostics       Date:  2020-08-08       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.